Last reviewed · How we verify

NCT04974710: DEFEND

Developing an US-MRI Biomarker Fusion Model for Endometriosis

Completed Last updated 20 December 2023
What this trial tests

trial testing Outpatient MRI in Endometriosis in 100 participants. Completed in 31 March 2023.

Timeline
18 March 2022
Primary endpoint
31 March 2023
31 March 2023

Quick facts

Lead sponsorPerspectum
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date18 March 2022
Primary completion31 March 2023
Estimated completion31 March 2023
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Perspectum

Who can join

Adults 18 to 40, female only, with Endometriosis or Reproductive System Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Single centre, prospective, observational, cohort study looking to develop a database representing the variability of disease and imaging seen in women with clinically diagnosed endometriosis, awaiting laparoscopic surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Outpatient MRI

Trials testing the same drug.

Other recruiting trials for Endometriosis

Currently open trials in the same condition.

Other Perspectum trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04974710.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing